Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats

Journal of Veterinary Pharmacology and Therapeutics

Volumn 25, Issue 5, 2002, Pages 371-378

  King, Jonathan N ^a   Strehlau, G ^a   Wernsing, J ^a   Brown, S A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; BENAZEPRILAT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CAT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOSE KIDNEY FUNCTION RELATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; INSULIN CLEARANCE; KIDNEY FAILURE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AREA UNDER CURVE; BENZAZEPINES; BLOOD PRESSURE; CAT DISEASES; CATS; CREATININE; FEMALE; KIDNEY; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; MALE;

ANIMALIA; FELIS CATUS; GLOMERULUS;

EID: 0036438928     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2885.2002.00427.x     Document Type: Article

References (21)

1. Amberger, C.N., Glardon, O., Glaus, T., Hörauf, A., King, J.N., Schmidli, H., Schröter, L. & Lombard, C.W. (1999) Effects of benazepril in the treatment of feline hypertrophic cardiomyopathy. Results of a prospective, open-label, multicenter clinical trial. Journal of Veterinary Cardiology, 1, 19-26.
2. Brown, S.A., Brown, C.A., Jacobs, G., Stiles, J., Hendi, R.S. & Wilson, S. (2001) Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency. American Journal of Veterinary Research, 62, 375-383.
3. Elliot, J., Barber, P.J., Syme, H.M., Rawlings, J.M. & Markwell, P.J. (2001) Feline hypertension: Clinical findings and response to antihypertensive treatment in 30 cases. Journal of Small Animal Practice, 42, 122-129.
4. Francis, G.S. (2000) ACE inhibitors in cardiovascular disease. New England Journal of Medicine, 342, 201-202.
5. Hoyer, J., Schulte, K.L. & Lenz, T. (1993) Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clinical Pharmacokinetics, 24, 230-254.
6. Hui, K.K., Duchin, K.L. & Kripalani, K.J. (1991) Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clinical Pharmacology and Therapeutics, 49, 457-467.
7. Kaiser, G., Ackermann, R., Dieterle, W. & Dubois, J.P. (1987) Determination of a new angiotensin converting enzyme inhibitor and its active metabolite in plasma and urine by gas chromatography-mass spectrometry. Journal of Chromatography, 419, 123-133.
8. King, J.N., Humbert-Droz, E. & Maurer, M. (1999) Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril. HCl. Journal of Veterinary Pharmacology and Therapeutics, 22, 360-367.
9. King, J.N., Maurer, M., Morrison, C., Mauron, C. & Kaiser, G. (1997) Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. Xenobiotica, 27, 819-829.
10. Lefebvre, H.P., Laroute, V., Concordet, D. & Toutain, P.L. (1999) Effects of renal impairment on the disposition of orally administered enalapril, benazepril and their active metabolites. Journal of Veterinary Internal Medicine, 13, 21-27.
11. Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J.E.F., Motolese, M., Ponticelli, C., Ritz, E. & Zuchelli, P. and the AIPRI Study Group (1996) Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. New England Journal of Medicine, 334, 939-945.
12. Narayanan, S. & Appleton, H.D. (1980) Creatinine: A review. Clinical Chemistry, 26, 1119-1126.
13. Nussberger, J., Juillerat, L., Perret, F., Waeber, B., Bellet, M., Brunner, J. & Ménard, J. (1989) Need for plasma angiotensin measurements to investigate converting-enzyme inhibition in humans. American Heart Journal, 117, 717-722.
14. Oguchi, H., Miyasaka, M., Koiwai, T., Tokunaga, S., Hora, K., Sato, K., Yoshie, T., Shioya, H. & Furuta, S. (1993) Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency. Clinical Pharmacokinetics, 24, 421-427.
15. Sica, D.A. (1992) Kinetics of angiotensin-converting enzyme inhibitors in renal failure. Journal of Cardiovascular Pharmacology, 20 (Suppl. 10), S13-S20.
16. The BENCH Study Group (1999) The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. Journal of Veterinary Cardiology, 1, 7-18.
17. Toutain, P.L., Lefebvre, H. & Laroute, V. (2000a) New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: Case of enalapril and benazepril in dogs. Journal of Pharmacology and Experimental Therapeutics, 292, 1094-1103.
18. Toutain, P.L., Lefebvre, H. & King, J.N. (2000b) Benazeprilat disposition and effect in the dog revisited using a pharmacokinetic/pharmacodynamic modeling approach. Journal of Pharmacology and Experimental Therapeutics, 292, 1087-1093.
19. 14C] - Benazepril hydrochloride in rat, dog and baboon. Drug Research, 39, 62-67.
20. Watanabe, T., Mishina, M. & Wakao, Y. (1999) Studies with the ACE inhibitor benazepril in an experimental model and in clinical cases of renal insufficiency in cats. Proceedings of American College of Veterinary Internal Medicine, 1999, 718.
21. Webb, R.L., Miller, D., Traina, V. & Gomez, H.J. (1990) Benazepril. Cardiovascular Drug Reviews, 8, 89-104.